Loading
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Previous close
$9.59
+$0.16 · +1.70%
Regular session · ET · Market data may be delayed.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Day range
Current $9.59
52-week range
Current $9.59
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
58
Mixed
Risk
77
High Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Day range
Current $9.59
52-week range
Current $9.59
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 24.99M USD | 9.73M USD |
| Cost of goods sold | 6.38M USD | — | — | — | — |
| Gross profit | −6.38M USD | — | — | 24.99M USD | 9.73M USD |
| Research and development | 99.13M USD | 99.32M USD | 106.04M USD | 71.25M USD | 48.94M USD |
| Selling, general, and administrative | 22.99M USD | 28.29M USD | 26.53M USD | 26.3M USD | 22.22M USD |
| Operating expenses | 115.73M USD | 127.62M USD | 152.04M USD | 97.54M USD | 71.16M USD |
| Interest income | 5.78M USD | 10.71M USD | 9.98M USD | 3.76M USD | 91K USD |
| Interest expense | 36K USD | 4K USD | 25K USD | 80K USD | 176K USD |
| Depreciation and amortization | 6.38M USD | 6.47M USD | 6.1M USD | 5.01M USD | 1.54M USD |
| Operating income | −122.11M USD | −127.62M USD | −152.04M USD | −72.55M USD | −61.43M USD |
| Net income | −116.8M USD | −117.12M USD | −142.66M USD | −69.79M USD | −62M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$352.67
3577.48% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 30, 2025 | 1:16 | — | — |
Stock split | Sep 16, 2020 | 1:7 | — | — |
Effective Dec 30, 2025
1:16
Effective Sep 16, 2020
1:7
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.22M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF901.09K0.00%93.7B USD0.05%$242.66+0.14%
iShares Micro-Cap ETFIWC225.74K0.02%1.49B USD0.60%$196.25+0.69%
U.S. Micro Cap Portfolio ETFDFMC150.01K0.00%7.81B USD0.43%$60.36+0.60%
Dimensional - US Small Cap ETFDFAS139.25K0.00%15.54B USD0.26%$82.20+0.18%
Avantis U.S. Small Cap Equity ETFAVSC56.56K—3.11B USD0.25%$73.23+0.55%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
